VCYT - Veracyte, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter 2026 after the close of market on Wednesday, November 4, 2026.
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced that new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial will be presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting.
Six oral presentations and two posters will highlight Decipher's prognostic and predictive value in identifying patients' risk of progression and likelihood of benefiting from treatment intensification Six oral presentations and two posters will highlight Decipher's prognostic and predictive value in identifying patients' risk of progression and likelihood of benefiting from treatment intensification
Veracyte (VCYT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Veracyte, Inc. (NASDAQ: VCYT - Get Free Report) insider John Leite sold 4,015 shares of Veracyte stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $40.00, for a total transaction of $160,600.00. Following the sale, the insider owned 124,329 shares in the company, valued at approximately $4,973,160. This
Squarepoint Ops LLC decreased its holdings in Veracyte, Inc. (NASDAQ: VCYT) by 76.8% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 14,853 shares of the biotechnology company's stock after selling 49,301 shares during the quarter. Squarepoint Ops LLC's holdings in
Corient Private Wealth LP lifted its stake in shares of Veracyte, Inc. (NASDAQ: VCYT) by 26.9% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 162,021 shares of the biotechnology company's stock after acquiring an additional 34,299 shares during the
Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey
Concurrent Investment Advisors LLC bought a new position in Veracyte, Inc. (NASDAQ: VCYT) during the second quarter, according to its most recent filing with the SEC. The firm bought 17,644 shares of the biotechnology company's stock, valued at approximately $1,036,000. Several other hedge funds have also bought and sold shares of the business.
On September 09, 2026, Veracyte Inc (VCYT) shares rose 3.3% to $43.85, reflecting a slight uptick amid a challenging price performance over the past month, whic
GenAI offers growth potential for VCYT, GMED and UFPT, but regulatory and technology risks are likely to challenge adoption across healthcare.
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 7:00 a.m. Eastern Time.
Canada Pension Plan Investment Board bought a new stake in Veracyte, Inc. (NASDAQ: VCYT) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 20,700 shares of the biotechnology company's stock, valued at approximately $1,216,000. Several other hedge funds and
Connor Clark and Lunn Investment Management Ltd. bought a new stake in Veracyte, Inc. (NASDAQ: VCYT) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 26,948 shares of the biotechnology company's stock, valued at approximately $1,583,000. Other hedge funds and other institutional investors have also recently
Bamco Inc. NY purchased a new stake in Veracyte, Inc. (NASDAQ: VCYT) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 650,686 shares of the biotechnology company's stock, valued at approximately $38,215,000. Bamco Inc. NY owned approximately 0.81% of Veracyte at the
VCYT's Afirma and Decipher sales momentum supports growth, while competition, macro pressures and rising investments remain key concerns.
Veracyte's 25.3% sell-off improves the entry price as strong core test demand and earnings growth face valuation, reimbursement and launch risks.
Veracyte (VCYT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Bank of America Corp DE grew its position in shares of Veracyte, Inc. (NASDAQ: VCYT) by 14.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,448,897 shares of the biotechnology company's stock after buying an additional 185,929 shares during the period.